Calithera Biosciences Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
35.99 M |
Public Float |
26.24 M |
Calithera Biosciences Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$1.73 |
Market Cap |
$175.8 M |
Shares Outstanding |
51.74 M |
Public Float |
33.08 M |
Address |
343 Oyster Point Boulevard South San Francisco California 94080 United States |
Employees | - |
Website | http://www.calithera.com |
Updated | 07/08/2019 |
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. |